<DOC>
	<DOCNO>NCT02819102</DOCNO>
	<brief_summary>This open-label , single sequence study evaluate effect BCX7353 hepatic intestinal cytochrome P450 enzymes use probe substrate drug healthy subject . Pharmacokinetics probe substrate drug measure prior follow administration multiple dos BCX7353 .</brief_summary>
	<brief_title>An Open-label Drug-Drug Interaction Study Evaluate Effect BCX7353 Cytochrome P450 Enzyme Activity Using Probe Substrates</brief_title>
	<detailed_description>This single centre , single sequence , open-label , study evaluate effect BCX7353 hepatic intestinal cytochrome P450 ( CYP ) 3A4 ( midazolam IV PO , respectively ) , CYP2C9 ( tolbutamide ) , CYP2C19 ( omeprazole ) CYP2D6 ( dextromethorphan ) enzyme activity use probe substrate drug healthy subject . Pharmacokinetics probe substrate drug measure prior follow administration multiple dos BCX7353 . Twenty healthy male female subject plan dose . Each subject receive follow treatment : Day 1 : 1 mg midazolam administer IV bolus simultaneously administration 500 mg tolbutamide , 40 mg omeprazole , 30 mg dextromethorphan orally . Day 2 : single oral dose 2 mg midazolam . Days 3 9 : 350 mg BCX7353 day . Day 10 : 1 mg midazolam administer IV bolus simultaneously administration 500 mg tolbutamide , 40 mg omeprazole , 30 mg dextromethorphan 350 mg BCX7353 , orally . Day 11 : single oral dose 2 mg midazolam along 350 mg BCX7353 .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Key Written inform consent Body mass index 18 32 kg/m2 Abides study restriction Attends study visit agree remain study center confinement period Acceptable birth control measure male subject woman childbearing potential Key Clinically significant medical history , current medical psychiatric condition . This include history clinically significant gastrointestinal , hematologic , renal , hepatic , bronchopulmonary , neurological , cardiac disease Clinically significant ECG finding , vital sign measurement laboratory/urinalysis abnormality screen baseline Poor ultra metabolizers CYP2C19 CYP2D6 Use counter prescription medication within 14 day dose anticipated use followup visit Use medication consumption substance know inhibit induce metabolic enzymes transporter within 30 day dose Participation investigational drug study within 90 day screen Recent current history alcohol drug abuse Regular recent use tobacco nicotine product Positive serology HBV , HCV , HIV Pregnant nursing Donation loss great 400 mL blood within 3 month Serious adverse reaction serious hypersensitivity drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>